As reviewed in part I of this report,1 primary PCI without antecedent fibrinolytic therapy has become widely accepted as the preferred reperfusion modality for patients with ST-segment–elevation myocardial infarction (STEMI) presenting at suitably equipped tertiary facilities. However, primary percutaneous coronary intervention (PCI) is not offered at 50% of US hospitals, and many of those that...

There is continued interest in the concept of limiting myocardial infarct size with adjunctive agents administered along with reperfusion injury; however, there remains considerable controversy in the literature. The purpose of this article is to review the medical literature on clinical trials performed during the past 3 years that have attempted to reduce myocardial infarct size by administra...

OBJECTIVE To investigate single neutrophil flow resistance in coronary artery disease, including myocardial infarction before initiation of reperfusion therapy. DESIGN Neutrophil flow resistance was measured in 93 subjects in five groups: (group 1) 28 patients within 12 hours after the onset of myocardial infarction, before reperfusion therapy; (group 2) 18 with unstable angina; (group 3) 13 ...

Objective Ischemia-reperfusion (I/R) injury is tissue damage occurring when blood returns to a after an ischemic phase. Reperfusion initiates cascade of acute inflammatory processes that end in cell death, malfunction, and necrosis. Edaravone (3-methy-1-pheny1-2-pyrazolin-5-one) powerful unique synthetic radical scavenger. In this research, the effects edaravone on I/R were investigated. Materi...